



## Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Nov 3, 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn<sup>®</sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control<sup>®</sup> platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

### Guggenheim Second Annual Healthcare Innovation Conference

- Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings

### Stifel 2025 Healthcare Conference

- Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings

### Jefferies 2025 London Healthcare Conference

- Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings

A webcast of the available presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghorntx.com](http://www.foghorntx.com), and will be available for 90 days.

### About Foghorn Therapeutics

Foghorn<sup>®</sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>®</sup> platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at [www.foghorntx.com](http://www.foghorntx.com) for more information on the Company, and follow us on [X](#) and [LinkedIn](#).

### Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.

[khellsvik@foghorntx.com](mailto:khellsvik@foghorntx.com)